FDA Continues To Speed PD-1/L1 Drugs To Market
Executive Summary
The four-month review of Merck’s Keytruda for first-line lung cancer is a reminder of how quickly the agency has acted on the immune checkpoint inhibitors.
You may also be interested in...
Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
The latest drug development news and highlights from our FDA Performance Tracker.
Pfizer’s Avelumab Poised For Speedy Review By FDA
Avelumab could be the fourth PD-1/L1 inhibitor to reach the market now that the US FDA has accepted Pfizer’s and Merck KGaA’s BLA for priority review in the treatment of metastatic Merkel cell carcinoma.
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
The latest drug development news and highlights from our FDA Performance Tracker.